FDA Issues Alert, Announces Recall of Common Thyroid Medication

Food and Drug Administration (FDA) headquarters in White Oak, Md., on Aug. 29, 2020. Andrew Kelly/Reuters

The U.S. Food and Drug Administration (FDA) on Thursday announced the recall of a thyroid medication after it was found that lots of the drug may be “subpotent.”

IBSA Pharma Inc. confirmed it is recalling Tirosint-SOL, or levothyroxine sodium, a medication used to treat an underactive thyroid gland. It said that the “voluntary recall has been initiated because these lots may be subpotent,” stated the announcement, published on the FDA’s website.